Royal Bank of Canada On Pace for Record High Close — Data Talk
Royal Bank of Canada (RY) is currently at $119.24, up $2.84 or 2.44%
--Would be new all-time high (Based on available data back to Oct. 16, 1995)
--Would be first new record closing high since Jan. 18, 2022, when it closed at $118.79
--On pace for largest percent increase since June 24, 2024, when it rose 2.5%
--Currently up 11 of the past 12 days
--Currently up six consecutive days; up 5.92% over this period
--Longest winning streak since Nov. 6, 2023, when it rose for six straight trading days
--Best six day stretch since the six days ending Dec. 20, 2023, when it rose 7.17%
--Up 6.71% month-to-date; on pace for best month since May 2024, when it rose 12.85%
--Up 17.91% year-to-date
--Up 31.26% from 52 weeks ago (Aug. 30, 2023), when it closed at $90.84
--Would be a new 52-week closing high
--Up 52.5% from its 52-week closing low of $78.19 on Oct. 27, 2023
--Traded as high as $119.52; new all-time intraday high (Based on available data back to Oct. 16, 1995)
--Up 2.68% at today's intraday high
All data as of 10:13:16 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 28, 2024 10:30 ET (14:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks